Airway inflammation in asthma and chronic obstructive pulmonary disease with special emphasis on the antigen-presenting dendritic cell: Influence of treatment with fluticasone propionate

Clinical and Experimental Allergy, Supplement

Volumn 29, Issue 2, 1999, Pages 116-124

  Hoogsteden, H C ^a   Verhoeven, G T ^a   Lambrecht, B N ^a   Prins, J B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antigen presenting cells; Asthma; Chronic obstructive pulmonary disease; Glucocorticoid treatment

Indexed keywords

CYTOKINE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; STEROID;

ALLERGIC ASTHMA; ANTIGEN PRESENTING CELL; BRONCHUS HYPERREACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATORY CELL; PRIORITY JOURNAL;

ANDROSTADIENES; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FORCED EXPIRATORY VOLUME; HUMANS; LUNG DISEASES, OBSTRUCTIVE; METHACHOLINE CHLORIDE;

EID: 0033010862     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (77)

1. Kay AB. Asthma and inflammation. J Allergy Clin Immunol 1991; 87:893-910.
2. Global initiative for asthma. National Institutes of Health/ National Heart, Lung and Blood Institute, 1995.
3. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155:852-7.
4. Nicod LP, Lipscomb MF, Toews GB, Weissler JC. Separation of potent and poorly functional human lung accessory cells based on autofluorescence. J Leukoc Biol 1989; 45:458-65.
5. Holt PG, Schon-Hegrad MA, Oliver J, Holt BJ, McMenamin PG. A contiguous network of dendritic antigen-presenting cells within the respiratory epithelium. Int Arch Allergy Appl Immunol 1990; 91:155-9.
6. Schon-Hegrad MA, Oliver J, McMenamin PG, Holt PG. Studies on the density, distribution, and surface phenotype of intraepithelial class II major histocompatibility complex antigen (Ia)-bearing dendritic cells (DC) in the conducting airways. J Exp Med 1991; 173:1345-56.
7. Gong JL, McCarthy KM, Telford J et al. Intraepithelial airway dendritic cells: a distinct subset of pulmonary dendritic cells obtained by microdissection. J Exp Med 1992; 175:797-807.
8. Christensen PJ, Armstrong LR, Fak JJ et al. Regulation of rat pulmonary dendritic cell immunostimulatory activity by alveolar epithelial cell-derived granulocyte macrophage colony-stimulating factor. Am J Respir Cell Mol Biol 1995; 13:426-33.
9. Lambrecht BN, Salomon B, Klatzmann D, Pauwels RA. Dendritic cells are required for the development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitized mice. J Immunol 1998; 160:4090-7.
10. Holt PG. Regulation of antigen-presenting cell function (s) in lung and airway tissues. Eur Respir J 1993; 6:120-9.
11. MacLean JA, Xia W, Pinto CE et al. Sequestration of inhaled particulate antigens by lung phagocytes. A mechanism for the effective inhibition of pulmonary cell-mediated immunity. Am J Pathol 1996; 148:657-66.
12. Bousquet J, Chanez P, Lacoste JY et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323:1033-9.
13. Azzawi M, Bradley B, Jeffery PK et al. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis 1990; 142:1407-13.
14. De Monchy JG, Kauffman HF, Venge P et al. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis 1985; 131:373-6.
15. Djukanovic R, Roche WR, Wilson JW et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142:434-57.
16. Laitinen LA, Laitinen A, Altraja A et al. Bronchial biopsy findings in intermittent or 'early' asthma. J Allergy Clin Immunol 1996; 98:S3-6, discussion S33-40.
17. Ying S, Humbert M, Barkans J et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1997; 158:3539-44.
18. Humbert M, Durham SR, Ying S et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against 'intrinsic' asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med 1996; 154:1497-504.
19. Robinson DS, Hamid Q, Ying S et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326:298-304.
20. Drazen JM, Arm JP, Austen KF. Sorting out the cytokines of asthma. J Exp Med 1996; 183:1-5.
21. Krug N, Frew AJ. The Th2 cell in asthma: initial expectations yet to be realised. Clin Exp Allergy 1997; 27:142-50.
22. Lopez AF, Sanderson CJ, Gamble JR et al. Recombinant human interleukin-5 is a selective activator of human eosinophil function. J Exp Med 1988; 167:219-24.
23. Clutterbuck EJ, Hirst EM, Sanderson CJ. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GM-CSF. Blood 1989; 73:1504-12.
24. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787-93.
25. Gleich GJ, Flavahan NA, Fujisawa T, Vanhoutte PM. The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperreactivity. J Allergy Clin Immunol 1988; 81:776-81.
26. Harnid Q, Azzawi M, Ying S et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991; 87:1541-6.
27. Humbert M, Corrigan CJ, Kimmitt P et al. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med 1997; 156:704-8.
28. Möller GM, Overbeek SE, Van Helden-Meeuwsen CG et al. Increased numbers of dendritic cells in the bronchial mucosa of atopic asthmatic patients: downregulalion by inhaled corticosteroids. Clin Exp Allergy 1996; 26:517-24.
29. Lambrecht BN, Pauwels RA, Bullock GR. The dendritic cell: its potent role in the respiratory immune response. Cell Biol Internat 1996; 20:111-20.
30. Kalinski P, Hilkens CM, Snijders A, Snijdewint FG, Kapsenberg ML. Dendritic cells, obtained from peripheral blood precursors in the presence of PGE2, promote Th2 responses. Adv Exp Med Biol 1997; 417:363-7.
31. Kalinski P, Schuitemaker JH, Hilkens CM, Kapsenberg ML. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol 1998; 161:2804-9.
32. Thompson AB, Daughton D, Robbins RA et al. Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. Am Rev Respir Dis 1989; 140:1527-37.
33. Ollerenshaw SL, Woolcock AJ. Characteristics of the inflammation in biopsies from large airways of subjects with asthma and subjects with chronic airflow limitation. Am Rev Respir Dis 1992; 145:922-7.
34. Saetta M, Di Stefano A, Maestrelli P et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993; 147:301-6.
35. Jeffery PK. Structural and inflammatory changes in COPD, a comparison with asthma. Thorax 1998; 53:129-36.
36. Lacoste JY, Bousquet J, Chanez P et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993; 92:537-48.
37. Grashoff WF, Sont JK, Sterk PJ et al. Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. Am J Pathol 1997; 151:1785-90.
38. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: Comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997; 155:449-53.
39. Ronchi MC, Piragino C, Rosi E et al. Role of sputum differential cell count in detecting airway inflammation in patients with chronic bronchial asthma or COPD. Thorax 1996; 51:1000-4.
40. Linden M, Rasmussen JB, Piitulainen E et al. Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. Am Rev Respir Dis 1993; 148:1226-32.
41. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153:530-4.
42. Schule R, Rangarajan P, Kliewer S et al. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 1990; 62:1217-26.
43. Yang-Yen HF, Chambard JC, Sun YL et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990; 62:1205-15.
44. Adcock IM, Lane SJ, Brown CR et al. Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma. J Immunol 1995; 154:3500-5.
45. Adcock IM, Lane SJ, Brown CR, Lee TH, Barnes PJ. Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med 1995; 182:1951-8.
46. Caldenhoven E, Liden J, Wissink S et al. Negative cross-talk between RclA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol 1995; 9:401-12.
47. Carlstedt-Duke J. The glucocorticoid receptor protein: a hormone-dependent transcription factor. Am J Respir Crit Care Med 1996; 154:S7-S9.
48. Finco TS, Baldwin AS. Mechanistic aspects of NF-κB regulation: the emerging role of phosphorylation and proteolysis. Immunity 1995; 3:263-73.
49. Siebenlist U, Franzoso G, Brown K. Structure regulation and function of NF-κB. Ann Rev Cell Biol 1994; 10:405-55.
50. Auphan N, DiDonato JA, Helmberg A, Rosette C, Karin M. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB. Synthesis Sci 1995; 270:286-90.
51. DiDonato JA, Saatcioglu F, Karin M. Molecular mechanisms of immunosuppression and anti-inflammatory activities by glucocorticoids. Am J Respir Crit Care Med 1996; 154:S11-S5.
52. Barnes PJ. Mechanisms of action of glucocorticoids in asthma. Am J Respir Crit Care Med 1996; 154:S21-S6.
53. Pene J, Rousset F, Briere F et al. IgE production by normal human B cells induced by alloreactive T cell clones is mediated by IL-4 and suppressed by IFN-γ. J Immunol 1988; 141:1218-24.
54. Zurawski G, De Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B-cells, but not on T cells. Immunol Today 1994; 15:16-9.
55. Wallen N, Kita H, Weiller D, Gleich GJ. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991; 147:3490-5.
56. Phillipps GH. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990; 84:19-23.
57. Bootsma GP, Dekhuijzen PN, Festen J, Mulder PG, van Herwaarden CL. Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma. Thorax 1995; 50:1044-50.
58. Chervinsky P, van As A, Bronsky EA et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group. J Allergy Clin Immunol 1994; 94:676-83.
59. Holliday SM, Faulds D, Sorkin EM. Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs 1994; 47:318-31.
60. Johnson M. Effect of fluticasone propionate on acute and chronic inflammation. Int Arch Allergy Immunol 1995; 107:441-2.
61. Johnson M. The anti-inflammatory profile of fluticasone propionate. Allergy 1995; 50:11-4.
62. Djukanovic R, Wilson JW, Britten KM et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145:669-74.
63. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90:32-42.
64. Overbeek SE, Rijnbeek PR, Vons C et al. Effects of fluticasone propionate on methacholine dose-response curves in nonsmoking atopic asthmatics. Eur Respir J 1996; 9:2256-62.
65. Olivieri D, Chetta A, Del Donno M et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 1997; 155:1864-71.
66. Booth H, Richmond I, Ward C et al. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med 1995; 152:45-52.
67. Nelson DJ, McWilliam AS, Haining S, Holt PG. Modulation of airway intraepithelial dendritic cells following exposure to steroids. Am J Respir Crit Care Med 1995; 151:475-81.
68. Holm AF, Fokkens WJ, Godthelp T et al. Effect of 3 months' nasal steroid therapy on nasal T cells and Langerhans cells in patients suffering from allergic rhinitis. Allergy 1995; 50:204-9.
69. Jeffery PK, Godfrey RW, Adelroth E et al. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis 1992; 145:890-9.
70. Bootsma GP, Koenderman L, Dekhuijzen PN et al. Effects of fluticasone propionate and beclomethasone dipropionate on parameters of inflammation in peripheral blood of patients with asthma. Allergy 1998; 53:653-61.
71. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155:542-8.
72. Postma DS, Steenhuis EJ, van der Weele LT, Sluiter HJ. Severe chronic airflow obstruction: can corticosteroids slow down progression? Eur J Respir Dis 1985; 67:56-64.
73. Postma DS, Peters I, Steenhuis BJ, Sluiter HJ. Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur Respir J 1988; 1:22-6.
74. Weir DC, Burge PS. Effects of high dose inhaled beclomethasone dipropionate, 750 micrograms and 1500 micrograms twice daily, and 40 mg per day oral prednisolone on lung function, symptoms, and bronchial hyperresponsiveness in patients with non-asthmatic chronic airflow obstruction. Thorax 1993; 48:309-16.
75. Paggiaro PL, Dahle R, Bakran I et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998; 351:773-80.
76. Grootendorst DC, Sont JK, Willems LNA et al. Comparison of inflammatory cell counts in asthma: Induced sputum vs bronchoalveolar lavage and bronchial biopsies. Clin Exp Allergy 1997; 27:769-79.
77. Burge PS, Calverney PM. Afor the ISOLDE group. Inhaled steroids in obstructive lung disease in Europe, the ISOLDE trial; protocol and progress. Am J Respir Crit Care Med 1994; 149:A21.